Torrent Pharmaceuticals is a branded-generics and CDMO pharma company whose first full quarter with JB Pharma amalgamated comes as the Indian pharma market accelerates but two company-specific drags — JB integration and a semaglutide injectable supply disruption — play out. The print will speak to whether the guided transient JB revenue impact stays contained at the EBITDA level, and whether management finally issues the combined-entity margin framework it has deferred twice.
| Results date | October 23, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 4,921 Cr |
| Previous quarter PAT | Rs. 566 Cr |
| Previous quarter EBITDA margin | 33.8% |
| Market cap | Rs. 173,405.9 Cr |
| CMP | Rs. 4,558.9 |
The Board of Directors is scheduled to meet on Friday, October 23, 2026, to approve the audited standalone and unaudited consolidated (with limited review) financial results for the quarter and half year ended September 30, 2026.
An earnings teleconference for Q2/H1 FY27 is scheduled the same day, October 23, 2026, at 5:30 PM.
The central question for Q2 FY27 is whether the guided transient revenue impact from merging JB Pharma brands and divisions into Torrent territories stays 'minor and transient' as management has stated, with normalization promised by Q4 FY27. The demand backdrop strengthened through the quarter — IPM value growth accelerated from +10.7% in August to +13.5% in September, with Q2 FY27 IPM growth of +14.7% outpacing Q1's +13.9% — and Torrent kept outgrowing the market with September monthly growth of +18.2%. Against that tailwind sit two live drags: the JB integration transition in Q2-Q3 FY27, and the semaglutide injectable stock-out through July-August that hit a franchise which had registered Rs. 50 Cr in Q1 sales against the Rs. 250 Cr annual target now flagged as uncertain. On costs, the price lever is unimpaired with IPM price growth of 6-6.2% in August-September, but China-sourced API procurement baselines running 15-25% above 2020 are a headwind against a base gross margin that ran ~78% in Q1 with management seeing up to 77% as sustainable. This session is also when management committed to issue the combined-entity margin guidance it deferred at the Q1 call ('waiting for one more quarter'), while the base-business guide of at least 0.5% FY27 margin improvement was already met in Q1 at 33.3% vs 32.8%. Leverage stood at 2.07x net debt/EBITDA at Q1 FY27 against a CFO-stated path of ~1-1.1x by FY28 and ~0.6x by FY29.
Performance vs previously stated guidance: Management deferred combined-entity margin guidance twice; this call is the stated point for a framework.
Strategic initiative updates expected
Follow-up needed on previously highlighted risks
Metric progress to monitor
Operating metric trajectory
Management deferred the combined-entity margin guidance at the Q1 FY27 call, saying it was 'waiting for one more quarter' for the merged entity to settle. The Q2 FY27 session is when this framework is due, though the CFO has said achieving year-three JB margin targets in year two is a possibility.
Management has said the Rs. 250 crore annual target is now uncertain after an injectable supply issue affected July and August sales, with affected SKUs representing about 20% of the franchise's monthly contribution. A revised franchise objective has been promised after observing recovery, and the oral brands with 94% oral market share in June are unaffected.
Management has guided a minor, transient revenue impact in some territories over 2-3 quarters from merging JB brands and divisions, with normalization expected by Q4 FY27. Synergies are expected to fully offset this at the EBITDA level for JB this year, with FY27 cost synergy realization now expected to exceed Rs. 100 crores vs the Rs. 90 crores initial target.
CFO Sudhir Menon has guided net debt/EBITDA of around 1-1.1x by FY28 and around 0.6x by FY29, from 2.07x at Q1 FY27 computed on underlying EBITDA of the combined company. Management has also said net debt/EBITDA will be kept below 3x-3.5x.
A third-party supplier accounting for 10-15% of Germany revenue ceased operations amid regulatory issues, and onboarding an alternate supplier takes at least 3-4 quarters. Management has refrained from guiding on Germany until the issue is resolved, saying it is 'still in the middle of the woods'; CC revenue was -9% in Q1 FY27.